Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
补肺颗粒用于慢性阻塞性肺疾病稳定期有效性和安全性随机、双盲、安慰剂、计量-效应对照Ⅱ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, dose-response controlled phase II clinical trial on the efficacy and safety of Bufei granules in the stable phase of chronic obstructive pulmonary disease
1.初步评价补肺颗粒用于慢性阻塞性肺疾病( COPD) 稳定期( 肺脾肾虚、 痰瘀互结证) 的有效性; 2.观察补肺颗粒的安全性; 3.探索补肺颗粒用于 COPD 稳定期的最佳用药剂量。
[Translation] 1. To preliminarily evaluate the effectiveness of Bufei Granules in the treatment of chronic obstructive pulmonary disease (COPD) in the stable stage (lung, spleen and kidney deficiency, phlegm and blood stasis syndrome); 2. To observe the safety of Bufei Granules; 3. To explore the optimal dosage of Bufei Granules in the stable stage of COPD.
100 Clinical Results associated with Research Institute Branch of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
0 Patents (Medical) associated with Research Institute Branch of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
100 Deals associated with Research Institute Branch of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
100 Translational Medicine associated with Research Institute Branch of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.